Autolus is a world-leading immunotherapy company founded by Dr Martin Pule at the University College of London in 2014. It is dedicated to the development of life-changing treatments that are designed to better recognise cancer cells and break down their defence mechanisms. Its innovative approach to T cell programming has the potential to offer therapies for patients with both haematological malignancies and solid tumours. It has premises in London, Munich and the USA, and is in the process of building a new 70,000 square foot manufacturing facility in Stevenage. https://www.autolus.com/